Change in Cognitive Functioning After Acute Antidepressant Treatment in Late-Life Depression

Michelle Culang, B.S., Joel R. Sneed, Ph.D., John G. Keilp, Ph.D.,
Bret R. Rutherford, M.D., Gregory H. Pelton, M.D.,
D. P. Devanand, M.D., Steven P. Roose, M.D.

Objective: Selective Serotonin Reuptake Inhibitors (SSRIs) are the most commonly prescribed medications for geriatric depression. The association of late-life depression and cognitive impairment has been well documented. However, there have been few placebo-controlled trials examining the impact of SSRIs on cognitive functioning. Design: Prepost neuropsychological (NP) data collected as part of an 8-week, double-blind, placebo-controlled trial of citalopram in depressed patients aged 75 years and older were used to examine change in cognitive functioning. Setting: University-affiliated outpatient psychiatry clinics. Participants: One hundred seventy-four community-dwelling men and women aged 75 years or older with nonpsychotic unipolar depression. Measurements: NP assessments included mental status (Mini-Mental State Examination), psychomotor speed (Wechsler Adult Intelligence Scale-III Digit Symbol Subtest), reaction time (Choice Reaction Time), visual-spatial skill (Judgment of Line Orientation), executive functioning (Stroop Color/Word Test), and memory (Buschke Selective Reminding Test). Results: Differences in the pattern of change by treatment group depended on responder status. Citalopram nonresponders were the only group to decline on verbal learning and psychomotor speed. Citalopram responders showed significant improvement in visuospatial functioning, when compared with nonresponders in either condition, but their improvement was not greater than responders on placebo. Citalopram responders showed greater improvement on psychomotor speed than citalopram nonresponders, but their improvement was not greater than placebo responders or nonresponders. Conclusions: Medication may have a deleterious effect on some aspects of cognition among patients aged 75 years and older who have not responded. This suggests that patients should not be maintained on a medication if they have not had an adequate response. (Am J Geriatr Psychiatry 2009; ●:000–000)

Key Words: Cognitive functioning, cognitive impairment, geriatric depression, late-life depression, citalopram
Selective Serotonin Reuptake Inhibitors (SSRIs) are the first-line of treatment in the geriatric depressed due to the efficacy, safety, and tolerability of its class. Cognitive impairment is common in late-life depression (LLD), particularly in memory, visuospatial functioning, information processing speed, and executive functioning. It is important to consider the impact that antidepressant treatment can have on cognition when treating depressed older adults.

Research that has examined the impact of SSRIs on the cognitive functioning of depressed older adults has been inconclusive because most studies have been limited by methodological constraints including small sample size or lack of an age-matched control group for comparison. For instance, treatment of LLD with sertraline led to an improvement in short- and long-term memory storage and retrieval and speed of processing. Although these results suggest that some aspects of cognition (i.e., memory and processing speed) improve with antidepressant treatment, it is difficult to determine whether the improvement was a function of repeat testing or medication because the design lacked a control group for comparison.

Studies using age-matched controls have shown that cognitive functioning of depressed older adults does not improve beyond the expected practice effect (practice effects refer to improvement due to repeat testing and are defined by the performance of a comparison condition, either an age-matched control group or a placebo comparison group that is not being treated with medication). For example, working and episodic memory, attention shifting, and processing speed did not improve after treatment with paroxetine to a greater degree than normal controls did with practice, regardless of responder status. Similarly, cognitive functioning showed no improvement beyond a practice effect among responders to either nortriptyline or paroxetine. These studies suggest that depressed older adults show little improvement as a function of treatment and cognitive impairment persists after an adequate trial of antidepressant medication.

Although such designs allow us to determine whether cognition changes as a function of antidepressant treatment, it does not allow us to conclude that the change (if any) is a result of treatment due to a lack of a placebo condition. However, there have been few placebo-controlled trials examining this issue. In one study, nortriptyline and phenelzine produced no change in cognition in depressed older adults, when compared with placebo, and this effect did not depend on responder status. However, the small sample size and limited number of responders made it difficult to determine the impact of responder status on change in cognition. Furthermore, this study was restricted to the use of a TCA and MAO-I. In another study, patients taking duloxetine showed significant improvement in verbal learning and memory, when compared with the placebo group. Therefore, it is unclear what impact medication, SSRIs in particular, has on cognitive functioning.

The purpose of this study was to examine the impact of antidepressant treatment on change in cognitive functioning. To accomplish this aim, we used neuropsychological (NP) data collected as part of the Old-Old Depression Study, a large (N = 174), randomized, double-blind, placebo-controlled trial of citalopram in depressed older adults (age >75 years). These data provided us with the methodological strength to address two questions: 1) do patients treated with citalopram show differential change in cognitive functioning over the 8 weeks, when compared with patients treated with placebo? 2) Does change in cognitive performance depend on responder status? To our knowledge, this is the first attempt to approach these issues using a placebo-controlled trial of an SSRI in an old-old (>75 years) depressed population.

METHOD

The procedures used in the multisite, randomized, placebo-controlled trial (RCT) have been previously described. Briefly, 174 community-dwelling men and women aged 75 years or older meeting Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition criteria (based on Structured Clinical Interview for Diagnostic and Statistical Manual of Mental Disorders-III-R interview) for nonpsychotic unipolar depression (single or recurrent) with a baseline 24-item Hamilton Rating Scale for Depression (HRSD) score ≥20 participated in this 8-week RCT. All patients began the trial with a 1-week single-blind placebo lead-in with the baseline visit con-
ducted at the end of the lead-in. Patients were randomized to citalopram 20 mg/day or matched placebo only if they continued to meet inclusion and exclusion criteria at the end of the placebo lead-in. At the end of Week 4, patients with a HRSD score >10 had the dose increased to two pills per day, i.e., 40 mg of citalopram or 2 placebo pills.

NP Test Battery

The test battery was designed to assess a number of cognitive functions pertinent to aging and major depression including mental status, psychomotor speed, reaction time, visual-spatial skill, attention, and memory. Three of the tests (Choice Reaction Time [CRT], Judgment of Line Orientation [JOLO], and Stroop) were presented on a Macintosh laptop computer and were written in the PsyScope programming language,19 whereas the other three tests (Mini-Mental State Exam, Buschke Selective Reminding Test [SRT], and Digit Symbol) were administered by hand. The tests included the 30-item Folstein Mini-Mental State Examination (MMSE)20 to estimate global cognitive functioning, the Wechsler Adult Intelligence Scale-III Digit Symbol Subtest21 as a measure of psychomotor speed, the CRT test adapted from Thorne et al.,22 the Stroop Color/Word Test23 to assess the response inhibition component of executive functioning, the JOLO24 as a measure of spatial judgment, and the Buschke SRT25 as a measure of verbal learning.

Missing Data

Missing data at baseline ranged from 0.6% on the MMSE and Buschke SRT to 9.8% on the JOLO and from 11.5% on the MMSE to 19.0% on the Stroop at follow-up. To accommodate missing data, we used multiple imputation using the PROC MI and MIANALYZE procedures in SAS. Multiple imputation is a simulation technique that replaces each missing datum with a set of \( m \) plausible values.26 This report is based on five imputed datasets (\( m = 5 \)), which is sufficient to obtain excellent results unless rates of missing data are exceptionally high.27 The imputed datasets are analyzed using standard statistical analyses, and results from the analyses from the \( m \) complete datasets are combined using Rubin’s rules26,28 to generate valid statistical inferences that reflect uncertainty due to missing values and improve the accuracy of the results.

Statistical Analyses

Before testing for differences in change in NP test performance, we used the PROC REG and PROC LOGISTIC procedures in SAS to test for differences at baseline between the two treatment conditions and the four treatment condition by responder status groups (see later). There were no differences on age, education, gender, baseline depression severity, responder status, or on any of the NP tests with the exception of baseline scores on the MMSE and Digit Symbol subtest of the Wechsler Adult Intelligence Scale-III. Therefore, we adjusted for baseline Digit Symbol and MMSE scores in the two treatment group analyses. When comparing the four patient groups (responder status by treatment condition), we found differences on education and baseline MMSE, CRT, and Buschke SRT scores. Therefore, we included these variables as covariates in the four group analyses. We also adjusted for site of study in all analyses, which we know from previous reports to be associated with outcome.16

To test for differences in change in NP test performance, we used data from the multiply imputed datasets and adopted a partial or regressed change approach to analyzing two time-point data29 using the PROC REG procedure in SAS. According to this approach, the endpoint NP test score is treated as the outcome variable, and the baseline test score is treated as a covariate. This effectively removes all correlation of the endpoint score from the baseline score and represents an improvement over simple change scores (subtracting baseline from endpoint), which tend to overcorrect the endpoint score by the baseline score due to unreliability of measurement.29 We first tested for differences in endpoint scores between treatment conditions using a dummy coded (citalopram = 1 and placebo = 0) variable. To test whether change in NP test performance depends on responder status (50% reduction from baseline HRSD score), we again used a dummy coded variable to designate the four patient groups (citalopram responders, citalopram nonresponders, placebo responders, and placebo nonresponders). Each covariate was centered at its respective mean, so the intercept corresponded to the mean of the reference.
group at endpoint and the unstandardized regression weights reflected the difference between the groups included in the model and the reference group (excluded from the model). All significance tests were evaluated at the 5% level.

RESULTS

Descriptive Statistics

Table 1 presents baseline demographic and clinical characteristics of the total sample, placebo and citalopram groups, and the four groups of patients classified by treatment condition and responder status. The average study participant was 79.57 years and completed about 2 years of college. Approximately 58% of the sample were women, average baseline depression severity was 24.32 on the 24-item HRSD, and 40% of the sample was classified as responders. The average MMSE score of the sample at baseline was 27.99, and 6.9% had a score of 24 or below.

To facilitate interpretation of the pattern of change in NP test performance as a function of treatment group, all NP scores were converted to z-scores based on mean values at baseline in the total sample. As can be seen in Fig. 1, NP test performance improved on each test in the placebo group, which is consistent with a practice effect. For the purposes of this report, practice effects refer to improvement in performance due to repeat testing and are defined on the basis of the performance of the placebo group. Differences from the placebo group (both positive and negative) reflect deviations from a practice effect and represent either improvement beyond a practice effect or the absence of a practice effect, possibly even decline. As can be seen in Fig. 1, the citalopram group improved on some tests and declined on others.

Hypothesis Testing

Table 2 shows the unadjusted means and standard deviations for all NP tests both pre and posttreatment for the citalopram and placebo groups and the four patient groups (treatment group by responder status). Adjusting for site and baseline MMSE and Digit Symbol, there was a statistically significant difference between the placebo and citalopram conditions at endpoint on the Buschke SRT. Specifically, patients treated with citalopram scored lower at endpoint than patients treated with placebo ($B = -2.74, SE = 1.41, t[1,087] = -1.94, 95% CI: -5.52 to 0.03, p = 0.05$).

We next compared the four groups of patients classified according to treatment condition and responder status on endpoint NP test performance. As can be seen in Table 2, citalopram responders scored significantly higher than both citalopram nonresponders ($B = -2.54, SE = 0.97, t[80.46] = -2.54, 95% CI: -4.38 to -0.53, p = 0.01$) and placebo nonresponders ($B = -2.47, SE = 0.89, t(217.31) = -2.77, 95% CI: -4.23 to -0.71, p = 0.01$) on the JOLO at endpoint. However, citalopram responders were not statistically significantly different than placebo responders at endpoint ($B = -1.81, SE = 1.02, t[111.56] = -1.78, 95% CI: -3.83 to 0.20, p = 0.08$). Looking at endpoint performance on the Buschke SRT, citalopram nonresponders were the only group to decline from pretest to posttest. Specifically, citalopram nonresponders scored lower (3.64 points) than placebo responders at endpoint ($B = -3.64, SE = 1.83, t(472.15) = -1.99, 95% CI: -7.23 to -0.05, p = 0.05$). Similarly, citalopram nonresponders were the only group to decline from pretest to posttest on the Digit Symbol. In particular, citalopram nonresponders scored lower than citalopram responders at endpoint

<table>
<thead>
<tr>
<th>Variable</th>
<th>Total Sample (n = 174)</th>
<th>Citalopram (n = 84)</th>
<th>Placebo (n = 90)</th>
<th>Citalopram Responders</th>
<th>Citalopram Nonresponders</th>
<th>Placebo Responders</th>
<th>Placebo Nonresponders</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age</td>
<td>79.57 (4.36)</td>
<td>79.82 (3.97)</td>
<td>79.33 (4.69)</td>
<td>79.30 (3.74)</td>
<td>80.19 (4.08)</td>
<td>80.05 (5.42)</td>
<td>78.89 (4.13)</td>
</tr>
<tr>
<td>Women (%)</td>
<td>58</td>
<td>54</td>
<td>62</td>
<td>60</td>
<td>49</td>
<td>61</td>
<td>63</td>
</tr>
<tr>
<td>Education (years)</td>
<td>13.77 (3.27)</td>
<td>13.82 (2.76)</td>
<td>13.72 (3.67)</td>
<td>12.76 (2.61)</td>
<td>14.56 (2.67)</td>
<td>13.30 (4.17)</td>
<td>13.99 (3.30)</td>
</tr>
<tr>
<td>HRSD</td>
<td>24.32 (4.12)</td>
<td>24.40 (4.31)</td>
<td>24.25 (3.95)</td>
<td>24.04 (4.50)</td>
<td>23.96 (4.13)</td>
<td>23.33 (3.46)</td>
<td>24.82 (4.10)</td>
</tr>
<tr>
<td>Responder (%)</td>
<td>40</td>
<td>41</td>
<td>38</td>
<td>100</td>
<td>0</td>
<td>100</td>
<td>0</td>
</tr>
<tr>
<td>MMSE</td>
<td>27.99</td>
<td>28.37 (1.61)</td>
<td>27.62 (2.46)</td>
<td>28.46 (1.40)</td>
<td>28.31 (1.74)</td>
<td>27.35 (2.38)</td>
<td>27.79 (2.50)</td>
</tr>
</tbody>
</table>
DISCUSSION

This was the first study to examine the impact of antidepressant treatment on change in cognitive functioning in depressed adults aged 75 years and older using data from an 8-week RCT. Although the placebo group showed a distinct practice effect from baseline to endpoint on all NP tests, the citalopram group improved on some tests but declined on others. However, the pattern of change depended on responder status. Specifically, citalopram nonresponders were the only group to decline in performance on verbal learning (Buschke SRT) and psychomotor speed (Digit Symbol). Citalopram responders showed significant improvement in visuospatial functioning (JOLO), when compared with nonresponders in either condition, but their improvement was not greater than responders on placebo. Similarly, citalopram responders showed greater improvement on psychomotor speed (Digit Symbol) than citalopram nonresponders, but their improvement was not greater than placebo responders or nonresponders. The findings indicate that the practice effect is impaired in some domains among nonresponders on medication. Therefore, these findings suggest that patients should not be maintained on a medication if they have not had an adequate response.

One possible explanation for the observed decline in verbal learning and psychomotor speed is that the overall level of cognitive functioning in the sample was low and the citalopram group had a disproportionately high number of cognitively impaired patients. This might explain why there was inconsistent improvement in the citalopram condition and why this study differs from previous placebo-controlled trials. However, the average MMSE score at baseline for the sample was 28, which is well within normal limits. Moreover, although there was a significant difference in MMSE scores between the treatment groups at baseline, it was the citalopram group that scored higher at baseline than the placebo group.

Another possibility is that brain lesions, which are associated with age and other risk factors such as hypertension and diabetes, were disproportionately represented in the citalopram condition. White matter hyperintensities (WMH) that are characteristic of LLD may interrupt frontal-striatal pathways that mediate cognitive functions that are commonly impaired in LLD. Furthermore, cognitive impairment is associated with the presence of WMH in LLD.

\[ B = -5.62, \text{SE} = 2.65, t(233.31) = -2.12, 95\% \text{ CI: } -10.84 \text{ to } -0.40, p = 0.04. \]
and deficits worsen as the lesions become more severe. However, there were no statistically significant differences in the percentage of patients in the citalopram group and the placebo group classified as having high lesion load, which was defined as a deep WMH rating of 2 or a subcortical gray matter rating of 3 on the Fazekas modified Coffey Rating Scale for Signal Hyperintensities.32

The decline in verbal learning may be particularly attributed to the anticholinergic effects of SSRIs. SSRIs have unique nonserotonergic pharmacologic profiles that are associated with distinct effects on cognitive functioning.33 Paroxetine, for example, may cause impairment in delayed verbal recall in healthy middle-aged adults and elderly subjects, whereas sertraline is associated with improvement in immediate and delayed verbal recall and verbal fluency.34,35 Although administration of citalopram is associated with improvement in working memory in depressed adults36 and increased memory consolidation in healthy adults,37 it is still unclear what effect citalopram can have on cognitive functioning of the geriatric depressed, a population that is especially vulnerable to the adverse effects of antidepressant medication.38

The observed decline in verbal learning and psychomotor speed in the citalopram group is consistent with a recent report from an epidemiological study of elderly depressed patients examining the relationship among depressive symptoms, cognitive impairment, and antidepressant use.39 Findings revealed that baseline depression scores predicted future mild cognitive impairment (MCI) but only among those using antidepressant medications at baseline. Taken together, these findings support the contention that nonresponders should not be maintained on medication that may have a negative impact on some aspects of cognitive functioning, which may facilitate the development of MCI.40

This study should be interpreted in the context of several limitations. First, there were statistically significant differences between the two treatment conditions and the four patient groups at baseline on several NP tests. However, these differences were adjusted for in the statistical models by including those tests as covariates. Second, it may be possible that including a small number of MCI patients (MMSE ≥24) in this study (N = 12) might have influenced our results. However, we ran the analyses...
with and without this group of patients, and the results were not different. Third, there was missing data, as is typically the case in clinical trials, and we accommodated for missing data using multiple imputation, a far superior method compared with traditional approaches using mean substitution or complete case analysis. Fourth, a somewhat limited NP battery was used. Only one aspect of executive functioning (i.e., response inhibition) was evaluated, and no formal test of attention was included in the study. However, these limitations are balanced by using data from the only randomized, placebo-controlled clinical trial of antidepressant treatment among depressed patients aged 75 years or older. Moreover, unlike other studies, there were an approximately equal number of responders in both treatment conditions, allowing for an adequate test of whether change in cognitive function across two treatments depends on responder status.

Our findings indicate that citalopram may interfere with the normal practice effect in verbal learning and psychomotor speed among patients who do not respond on medication. Although responders on medication may improve in some domains, their improvement does not exceed the expected practice effect observed in patients randomized to placebo. This raises the important clinical issue that, although two treatments may be equivalent with regard to response, they may have differential effects on cognitive functioning, especially in a cognitively vulnerable population. Our findings suggest that nonresponders should not be maintained on medication that may have a negative effect on some aspects of cognitive functioning.

This work was supported by a grant from Forest Laboratories and National Institute of Mental Health grants T32 MH20004 (to SPR) and K23 MH075006 (to JRS) and from Eli Lilly and Novartis (to DPD).

SPR has received consultant fees from Forest Laboratories, Wyeth Pharmaceuticals, Sanofi-Aventis, Pfizer, and Sierra Pharmaceuticals and DPD has received consultant fees from Glaxosmithkline, Acadia, and Sanofi-Aventis.

References

AUTHOR PLEASE ANSWER ALL QUERIES

1—Kindly check whether the minor edit made to the article title is appropriate.
2—Kindly spell out the first name of the author “D.P. Devanand.”
3—Please note that the page foot note has been moved to the text as per journal style.
4—Kindly spell out TCA and MAO-I.
5—Kindly check whether tables are OK as typeset.
6—Kindly check whether the grant information and the disclosure are OK as typeset.
7—Please note that Ref. 19 (original number) has been deleted as it seemed to be repetition of Ref. 16 and also the corresponding references have been renumbered as to make it sequential per journal style.
8—Kindly provide department/division name (if any) for the affiliations.